Thermo Cardiosystems says HeartMate sales set for record:
This article was originally published in Clinica
Executive Summary
Thermo Cardiosystems is predicting a buoyant fourth quarter with sales up more than 15% over the previous quarter to $17 million. Its HeartMate left ventricular assist system (LVAS) sales have risen over 35% in the same period, to $7 million. The HeartMate is the only LVAS system approved in the US. Thermo Cardiosystems, which is a subsidiary of Thermo Electron, reports its full year figures in February.
You may also be interested in...
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.